Treatment with methylation-controlled J protein (MCJ)

Patent metadata

Field	Value
Publication number	US-10792330-B2
Application number	US-201715805534-A
Country	US
Kind code	B2
Filing date	Nov 7, 2017
Priority date	Jul 11, 2012
Publication date	Oct 6, 2020
Grant date	Oct 6, 2020

Abstract

The invention relates, in part, to methods and compositions that are useful to modulate metabolic function of cells in vivo or in vitro. In some aspects the invention includes methods and/or compositions that increase metabolism in cells, tissues, organs, and/or subjects. In certain aspects the invention includes methods and/or compositions useful to decrease metabolism in cells, tissues, organs, and/or in subjects.

First claim

What is claimed is:

1. A method of increasing mitochondrial metabolism in a CD 8+ T cell, the method comprising contacting a CD 8+ T cell in vitro with an exogenous MCJ-modulating compound that decreases an MCJ activity in an amount effective to decrease MCJ activity and increase mitochondrial metabolism in the CD 8+ T cell, wherein the MCJ-modulating compound comprises an MCJ siRNA molecule.

2. The method of claim 1 , wherein decreasing the MCJ activity comprises decreasing a level or function of MCJ polypeptide in the CD 8+ T cell.

3. The method of claim 1 , wherein mitochondrial metabolism is mitochondrial respiration.

4. The method of claim 1 , wherein the MCJ-modulating compound genetically targets MCJ expression and reduces the amount of MCJ polypeptide expressed in the CD 8+ T cell.

5. The method of claim 1 , wherein the MCJ-modulating compound further comprises a mitochondrial targeting agent.

6. The method of claim 1 , wherein the CD 8+ T cell is an ex vivo CD 8+ T cell.

Assignees

• Univ Of Vermont And State Agricultural College

Inventors

• Rincon Mercedes
• Hatle Ketki M

Classifications

• A61P3/02

  Nutrients, e.g. vitamins, minerals · CPC title

• A61K48/00

  Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title

• G01N33/68

  involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)} · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title